Desam Roda

Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives

Luminal-B breast cancer and novel therapeutic targets

Targeted therapies for breast cancer

Cancer immunotherapies targeting the PD-1 signaling pathway

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis

Combinatorial drug therapy for cancer in the post-genomic era

mTOR Signaling in Growth Control and Disease

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Hypoxia and the extracellular matrix: drivers of tumour metastasis

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

CCR9 in cancer: oncogenic role and therapeutic targeting

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy

Ki67 expression in breast cancer

Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation

The PI3K Pathway in Human Disease

Metastatic colonization by circulating tumour cells

Inflammatory bone loss: pathogenesis and therapeutic intervention

Emerging targeted agents in metastatic breast cancer

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer

Strategies for modern biomarker and drug development in oncology

A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.